These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 4075858)

  • 21. In vitro study with ciprofloxacin: interpretive criteria of agar diffusion test according to standards of the NCCLS and DIN.
    Grimm H
    Am J Med; 1987 Apr; 82(4A):376-80. PubMed ID: 3578326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic activity of amikacin with aztreonam against Pseudomonas aeruginosa and other gram-negative organisms.
    Greenberg RN; Bollinger M; Compton J
    Clin Ther; 1986; 8(3):354-8. PubMed ID: 3087621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colistin susceptibility testing by Etest and disk diffusion methods.
    Galani I; Kontopidou F; Souli M; Rekatsina PD; Koratzanis E; Deliolanis J; Giamarellou H
    Int J Antimicrob Agents; 2008 May; 31(5):434-9. PubMed ID: 18328674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tentative disk diffusion susceptibility interpretive criteria for pefloxacin.
    Fuchs PC; Barry AL; Jones RN; Thornsberry C
    J Clin Microbiol; 1986 Sep; 24(3):448-50. PubMed ID: 3463566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aztreonam.
    Outman WR
    Conn Med; 1987 Sep; 51(9):611-3. PubMed ID: 3311617
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical laboratory approach for estimating the effective administrative dose of latamoxef. Significance of a 4-category system interpretation of the latamoxef disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1987 Nov; 40(11):1906-16. PubMed ID: 3327966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interpretative criteria for the agar diffusion susceptibility test with azithromycin.
    Barry AL; Jones RN
    J Antimicrob Chemother; 1988 Nov; 22(5):637-41. PubMed ID: 2850289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporin.
    Jones RN; Erwin ME
    J Clin Microbiol; 1991 Dec; 29(12):2890-2. PubMed ID: 1757568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates.
    Nagy E; Justesen US; Eitel Z; Urbán E;
    Anaerobe; 2015 Feb; 31():65-71. PubMed ID: 25464140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C
    J Clin Microbiol; 1986 Mar; 23(3):634-6. PubMed ID: 3754266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of aztreonam, cefuroxime and ceftazidime against gram-negative rods isolated from hospital patients with urinary tract infection.
    Webb G; Robbins MJ; O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Int J Clin Pharmacol Res; 1987; 7(3):203-5. PubMed ID: 3298085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical laboratory approach to evaluate administration dose of arbekacin. Reevaluation of in vitro MIC break points in the disk susceptibility test].
    Matsuo K; Uete T
    Jpn J Antibiot; 1994 Aug; 47(8):1041-52. PubMed ID: 7933533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro studies with cefotaxime: disk diffusion susceptibility tests.
    Shadomy S; Chan EL
    J Clin Microbiol; 1982 Aug; 16(2):213-7. PubMed ID: 6288761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical laboratory approach for estimating effective administrative dose of tobramycin. Reevaluation of in vitro MIC break points of disk susceptibility test].
    Uete G; Matsuo K; Uete T
    Jpn J Antibiot; 1989 Sep; 42(9):1888-99. PubMed ID: 2810752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro antibacterial activity of apalcillin on aerobic bacteria and the regression curve].
    Soussy CJ; Duval J; Chanal M; Sirot D; Bergogne-Bérézin E; Joly-Guillou ML; Malbruny B; Morel C
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):660-4. PubMed ID: 3054743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How and why aztreonam works.
    Rittenbury MS
    Surg Gynecol Obstet; 1990; 171 Suppl():19-23. PubMed ID: 2244291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam.
    van Ogtrop ML; Guiot HF; Mattie H; van Strijen E; Sekh BR; van Furth R
    Antimicrob Agents Chemother; 1991 May; 35(5):983-5. PubMed ID: 1854181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.